Figure 4. Probability of target attainment (PTA) (fAUC0-24h/MIC = 47.05) in simulated patients with normal renal function or severe renal impairment after selective dose adjustment of nemonoxacin. RI: renal impairment; HC: healthy control; LD: loading dose; MD: maintaining dose.Figure 5. Cumulative urine excretion profile in severe patients with renal impairment and healthy controls following single oral administration of nemonoxacin capsule (0.5 g). Data represent mean ± standard deviation.